June 2012 Editor's Picks: Products from EMD Millipore and Meissner Filtration Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

June 2012 Editor's Picks: Products from EMD Millipore and Meissner Filtration Products

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

EMD Millipore
Single-use bioreactor is designed for process development or pilot-scale cell culture

EMD Millipore’s Mobius CellReady 50-L single-use, stirred tank bioreactor is designed for process development and pilot-scale mammalian cell culture. The rigid base and top panel design of the bioreactor process container enables simple, reliable, and robust one-way installation. Mobius SensorReady technology allows the user to configure process monitoring at the point of use and enables integration of new sensor technologies. The system is available as a turnkey solution complete with Finesse automation or as modules that can be integrated with the customer’s platform of choice.


Meissner Filtration Products
Containers support disposable biocontainer assemblies

Meissner Filtration Products’ QuaDrum containers for Meissner’s TepoFlex 3D biocontainer assemblies have a square design rather than the industry standard cylindrical design.  The design makes efficient use of floor space, and can be used with a stainless steel dolly for intra-facility transport. The reusable, polyethylene containers are chemically resistant and can be sanitized. Slotted lids offer access to tubing and filters or solid lids completely cover the assembly.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Equipment and Processing Report,
Click here